| About the author: |
I. P. Dunaieva |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The purpose of our study was to determine of diagnostic and prognostic role of cystatin C in the development of cardiorenal syndrome in the case of arterial hypertension syndrome and maximum comorbid conditions. 111 patients and 20 persons of the control group were examined. In the current examination process, they were divided into 4 groups depending on the presence of comorbid pathology in them: patients with arterial hypertension – 1 group – 22 people; patients with arterial hypertension in combination with obesity – group 2 – 30 people; arterial hypertension in combination with type 2 diabetes – group 3 – 31 people; patients with hypertension, type 2 diabetes and obesity – group 4 – 28 people. The level of cystatin C in the examined cases with arterial hypertension and various comorbidities was significantly higher compared to individuals of the control group. Significant effect of the cardiotrophin-1 residue on cystatin C. An increased level of cystatin C is associated with an increase in blood pressure, the level of cardiotrophin-1, catestatin, which ensures its role in the early development of nervous and cardiovascular complications in patients with arterial hypertension with various hormonal comorbidities and confirms the significance of the activity of adipose tissue in the development of kidney dysfunction. |
| Tags |
arterial hypertension,type 2 diabetes mellitus,obesity,cystatin C,cardiorenal syndrome |
| Bibliography |
- Angelidis C, Deftereos S, Giannopoulos G, Anatoliotakis N, Bouras G, Hatzis G, et al. Cystatin C: an emerging biomarker in cardiovascular disease. Curr Top Med Chem. 2013;13(2):164–79. doi: 10.2174/1568026611313020006.
- Chung ES, Meyer TE. Cardiorenal syndrome: misgivings about treatment options, clarity on prognosis. J Card Fail. 2015 Feb;21(2):116–8. doi: 10.1016/j.cardfail.2014.11.011.
- Dedual MA, Wueest S, Challa TD, Lucchini FC, Aeppli TRJ, Borsigova M, et al. Obesity-Induced Increase in Cystatin C Alleviates Tissue Inflammation. Diabetes. 2020 Sep;69(9):1927–1935. doi: 10.2337/db19-1206.
- Dejenie TA, Abebe EC, Mengstie MA, Seid MA, Gebeyehu NA, Adella GA, et al. Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2023 Apr 4;14:1124367. doi: 10.3389/fendo.2023.1124367.
- De Vecchis R, Baldi C. Cardiorenal syndrome type 2: from diagnosis to optimal management. Ther Clin Risk Manag. 2014 Nov 12; 10:949–61. doi: 10.2147/TCRM.S63255.
- Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular filtration rate. Curr Opin Nephrol Hypertens. 2015 May;24(3):295-300. doi: 10.1097/MNH.0000000000000115.
- Fernando S, Polkinghorne KR. Cystatin C: not just a marker of kidney function. J Bras Nefrol. 2020 Mar;42(1):6–7. doi: 10.1590/2175-8239-JBN-2019-0240.
- Krstic D, Tomic N, Radosavljevic B, Avramovic N, Dragutinovic V, Skodric SR, et al. Biochemical Markers of Renal Function. Curr Med Chem. 2016;23(19):2018–40. doi: 10.2174/0929867323666160115130241.
- Levey AS, Fan L, Eckfeldt JH, Inker LA. Cystatin C for glomerular filtration rate estimation: coming of age. Clin Chem. 2014 Jul;60(7):916–9. doi: 10.1373/clinchem.2014.225383.
- Luo J, Wang LP, Hu HF, Zhang L, Li YL, Ai LM et al. Cystatin C and cardiovascular or all-cause mortality risk in the general population: A meta-analysis. Clin Chim Acta. 2015 Oct 23; 450:39–45. doi: 10.1016/j.cca.2015.07.016.
- Magnusson M, Molvin J, Engström G, Svensson-Färbom P, Persson M, Christensson A, et al. Cystatin C and Risk of Diabetes and the Metabolic Syndrome – Biomarker and Genotype Association Analyses. PLoS One. 2016 May 24;11(5): e0155735. doi: 10.1371/journal.pone.0155735
- Onopiuk A, Tokarzewicz A, Gorodkiewicz E. Cystatin C: a kidney function biomarker. Adv Clin Chem. 2015; 68:57–69. doi: 10.1016/bs.acc.2014.11.007.
- Satirapoj B. Tubulointerstitial Biomarkers for Diabetic Nephropathy. J Diabetes Res. 2018 Feb 8; 2018:2852398. doi: 10.1155/2018/2852398.
- Van der Laan SW, Fall T, Soumaré A, Teumer A, Sedaghat S, Baumert J, et al. Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study. J Am Coll Cardiol. 2016 Aug 30;68(9):934–45. doi: 10.1016/j.jacc.2016.05.092.
|
| Publication of the article |
«World of Medicine and Biology» №3(85), 2023 year, 065-069 pages, index UDK 616.12-008.331.1+616.379-008.64]-056.257-06:616.61-078 |
| DOI |
10.26724/2079-8334-2023-3-85-65-69 |
